Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.
Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.
Core Business
Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.
Latest Achievements and News
As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.
Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).
Financial Condition and Partnerships
Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.
About Merus N.V.
Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.
Merus N.V. (MRUS) has announced the selection of two abstracts for the upcoming AACR Annual Meeting 2023 on April 17, where interim clinical data for bispecific antibody petosemtamab will be presented. The first presentation will focus on its efficacy in treating head and neck squamous cell carcinoma, while the second will cover its use in advanced gastric/esophageal adenocarcinoma. These findings are part of a phase 1 trial. An investor call is scheduled for the same day at 6:30 p.m. ET. Petosemtamab targets cancer stem cells and demonstrates promising mechanisms for inhibiting tumor growth, marking a significant advancement in oncology.
Merus N.V. (Nasdaq: MRUS) reported its financial results for 2022, highlighting a net loss of $131.2 million, an increase from $66.8 million in 2021. Collaboration revenue decreased by $7.5 million to $41.6 million, primarily due to reduced revenue from partnerships with Lilly and Incyte. R&D expenses surged by $51.2 million to $149.4 million, driven by clinical services and personnel costs. The company maintains a strong cash position with $326.7 million in cash and equivalents, expected to fund operations into the second half of 2025. Key updates on clinical trials are anticipated in 2023 for Zenocutuzumab and Petosemtamab, indicating potential advancements in cancer treatment.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. Lundberg's fireside chats are scheduled for:
- Guggenheim Healthcare Talks/Oncology Conference on February 8, 2023, from 11:20-11:45 a.m. ET
- SVB Securities Global Biopharma Conference on February 14, 2023, from 3:40-4:10 p.m. ET
- Citi's 2023 Oncology Leadership Summit on February 23, 2023, from 10:00-11:00 a.m. ET
Webcasts of these presentations will be available live on the company's Investors page, with archived versions accessible for a limited time post-event.
Merus N.V. (Nasdaq: MRUS) announces its 2023 outlook emphasizing progress in oncology treatments. The company has treated over 150 patients with NRG1+ cancer using zenocutuzumab (Zeno) monotherapy and aims for a BLA filing with the FDA. Upcoming clinical updates are expected for petosemtamab and MCLA-129 in 2023. Merus reported sufficient cash reserves to fund operations into the second half of 2025. Key collaborations with Incyte and Loxo Oncology continue to advance various bispecific antibody programs, showcasing Merus' commitment to innovative cancer treatments.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will speak at the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET. The presentation will be available via webcast on the company's Investors page and archived for later viewing. Merus specializes in developing full-length multispecific antibodies, known as Biclonics® and Triclonics®, with potential applications in oncology.
Merus N.V. (MRUS) has provided a clinical and financial update for Q3 2022. Their lead program, MCLA-129, shows clinical activity with promising early efficacy data presented at the ENA Symposium. The FDA recommends further patient enrollment in the eNRGy trial for Zenocutuzumab (Zeno) to support a Biologics License Application (BLA) for NRG1+ cancers. Collaboration revenue decreased by $7.1 million year-over-year. Operating expenses increased, leading to a greater net loss of $24.6 million. As of September 30, 2022, Merus has $372.9 million in cash, sufficient to fund operations beyond 2024.
Merus N.V. (Nasdaq: MRUS) has reported interim clinical data for MCLA-129, a bispecific antibody targeting EGFR and c-MET. The phase 1/2 trial showed a favorable safety profile with no dose-limiting toxicities. Antitumor activity was noted in heavily pretreated patients across various tumor types, including confirmed partial responses. The initial recommended dose for phase 2 is set at 1500 mg biweekly. Key details will be discussed in an investor call on October 26. These findings highlight MCLA-129's potential efficacy as a treatment for advanced solid tumors, including non-small cell lung cancer (NSCLC).
Merus N.V. (MRUS) announced promising results from the phase 1/2 trial of MCLA-129, a bispecific antibody targeting EGFR and c-MET for advanced non-small cell lung cancer (NSCLC). The drug was well-tolerated, with no dose-limiting toxicities observed. Preliminary data showed anti-tumor activity in 13 evaluable patients, with two achieving partial responses. The recommended phase 2 dose is 1500 mg. Further data will be presented at the ENA Symposium on October 28, 2022, along with an investor call detailing the program update on October 26, 2022.
Merus N.V. (Nasdaq: MRUS) announced the selection of an abstract for a poster presentation at the 34th EORTC/NCI/AACR Symposium, scheduled for October 28, 2022. The poster will focus on MCLA-129, a bispecific antibody targeting EGFR and c-MET, currently in phase 1/2 study for advanced non-small cell lung cancer (NSCLC) and other solid tumors. Preclinical studies suggest MCLA-129 may effectively treat TKI-resistant NSCLC. The abstract will be available on October 12, 2022, and the poster can be accessed during the conference and on Merus' website.
FAQ
What is the current stock price of Merus N.V. Common Shares (MRUS)?
What is the market cap of Merus N.V. Common Shares (MRUS)?
What is the core business of Merus N.V.?
What are some of Merus' key product candidates?
What significant recent achievement has Merus reported?
What are Biclonics®?
What is the status of MCLA-145 and MCLA-129?
What are Multiclonics®?
Who are Merus' key partners?
What are the financial strategies of Merus?
What is the purpose of the latest capital raise by Merus?
Where can I find more information about Merus N.V.?
